Milichi.... I have a short time to live, perhaps............ I feel like my good friend Steve McQueen when he moved to Mexico ............ he was blowing up with cancer.
I am looking for some bizarre cures.......................like a sh*t load of garlic, a bunch of carrots........ or whatever!
******
The truth of ALL THINGS may be that spending at least an hour on FR each day (by every American voter)............... just may be the cure of all things.
Bless FR............... and please eat well.
sw
I just said a prayer that you may fully recover. Chewing a carrot right now.
The Huanglian Anticancer Option (SK 1046) The Huanglian Anticancer Option (SK 1046) Summary of Invention
Huanglian (coptis chinensis) is a traditional Chinese herb used to treat various inflammatory conditions. However, its role as an anticancer drug has not been clearly defined.
This invention discloses results that Huanglian potently inhibits the growth of gastric, breast, and colon cancer cells in vitro in a dose-dependent manner. This inhibition is associated with suppression of cyclin B1 protein and cyclin kinase 1 (CDC2 kinase) activity.
A Phase I clinical study in patients with advanced solid tumors is currently underway.
In this study, patients will receive escalating doses of the aqueous extract of Huanglian. In a separate study, cells from the gastric cancer cell line MKN 74 exhibited an 80 percent reduction in growth when exposed to the serum of patients treated with Huanglian. Results of this study could be applied to pilot a methodology for screening, identifying, and quantifying anticancer metabolites in Huanglian and other herbs. Advantages
Huanglian inhibits the growth of cancer, e.g., gastric, breast, and colon cancer, in a dose-dependent manner.
Acts by suppression of cyclin-B1 and CDC kinase activity. Novel cancer drug that potentiates Taxol-mediated apoptosis.
Excellent safety profile. Oral administration of the drug leads to greater compliance among patients.
Assay method to screen, identify, and quantitate active anticancer metabolites from natural products.
Areas of Application Therapeutic drug. Stage of Development Phase I clinical trials progress in patients with advanced solid tumors.
Lead Inventor Dr. Gary K. Schwartz Patent Information Worldwide patent protection available.
US patent prosecution ongoing. PCT application published as WO 2004/040259. References LI XK. Mol Pharmacol. 58(6):1287-93 (2000). Contact Information Leena Prabhu, PhD, MBA Tel: 212-639-6181; Fax: 212-717-3439 E-mail: prabhul@mskcc.org
Prayers going out for you...
please let us, your freeper friends , understand what is going on in your life.....please.....
beyond the sea,
Keeping you in my thoughts and prayers.
Continue to enjoy FR and the outdoors. Two wonderful things in this world!